The Trump administration is moving to establish a major national stockpile of critical minerals, with a $10 billion federal loan and private investment, aiming to reduce reliance on foreign supplies for key technologies.
Despite solid revenue growth, Microvast Holdings (NASDAQ: MVST) has seen its share price collapse over the past five years, erasing billions in market value and testing the patience of long-term investors.
U.S. equities edged higher Monday, buoyed by a rebound in semiconductor and AI infrastructure stocks, alongside a surge in rare earth companies following a new strategic initiative. Gains were tempered by falling energy shares, cryptocurrency volatility, and ongoing concerns over a partial government shutdown.
Former President Donald Trump's recent endorsement of a weaker U.S. dollar is prompting investors to position for potential policy shifts. We examine the market implications and three investment avenues gaining traction.
The Swiss watchmaker reported a dip in 2025 profits amid currency headwinds and strategic investments, but forecasts a return to broad-based growth next year, buoyed by robust second-half sales and strong performance in key markets like the Americas.
In a landmark agreement announced by former President Trump and Prime Minister Modi, the U.S. will slash tariffs on Indian goods, while New Delhi commits to halt Russian oil imports and significantly increase purchases of American energy and goods.
Primrose Candy Co., an Illinois-based confectioner with roots stretching back to the Great Depression, has filed for Chapter 11 bankruptcy, citing mounting debts, rising costs, and shifting consumer tastes that have eroded its once-stable business.
The century-old outdoor apparel brand, famed for pioneering the quilted down jacket, is preparing to close its North American retail footprint while its licensing and e-commerce operations continue under new management.
The FDA has issued a complete response letter for Aquestive Therapeutics' sublingual epinephrine film Anaphylm, citing concerns over packaging and user instructions. The company aims to address the issues and resubmit its application by the third quarter of this year.
Life sciences and diagnostics firm Revvity (RVTY) closed 2025 with results surpassing internal targets, driven by robust diagnostics performance. While management provided initial 2026 guidance, it remains conservative, banking on market stabilization rather than a broad recovery.
Synthetic biology leader Twist Bioscience reported strong Q1 FY2026 results, with revenue climbing 17% year-over-year to $103.7 million. Management highlighted accelerating demand from AI-powered drug discovery and reiterated its path to adjusted EBITDA breakeven by Q4 FY2026.
As major indices climb, investors are sifting through economic crosscurrents to find resilient tech innovators. We examine three companies—Veracyte, monday.com, and Zeta Global—whose strategic moves and financial momentum position them for potential growth.
Amid a backdrop of cautious market optimism, companies with significant insider ownership are drawing investor attention. We examine three firms where those closest to the business are putting their money, spanning biotech, advanced semiconductors, and regional banking.
NAPCO Security Technologies (NSSC) reported strong fiscal second-quarter results, with record revenue and expanding profitability. The company highlighted the sustained momentum of its high-margin recurring service model and announced a dividend increase.
A new economic report finds that while inflation has cooled, recent tariff policies have kept prices higher than they otherwise would be, as the Supreme Court weighs the legality of the measures.
Investment firm Artemis Investment Management has established a significant new position in Commercial Metals Company, a leading steel producer and recycler, signaling confidence in the firm's strategic direction and growth prospects despite a recent share price surge.
Micron Technology is making a decisive shift from volatile consumer memory markets, channeling a massive $24 billion investment into Singapore to build advanced fabrication and packaging facilities aimed squarely at the booming AI data center sector.
After a decade of development and multiple clinical setbacks, Sanofi's venglustat has met its primary goal in a Phase 3 trial for Type 3 Gaucher disease, offering new hope for neurological symptoms. The drug, however, failed a separate late-stage study for Fabry disease.
Fourth-quarter earnings for S&P 500 companies are significantly outperforming expectations, led by robust growth in industrial and tech sectors, as investors await a busy week of corporate results and key economic data.
A draft proposal from disaster response firm Gothams LLC, obtained by The Guardian, outlined terms for a trucking and logistics monopoly in Gaza that would guarantee extraordinary returns, raising questions about oversight and ethics in post-conflict rebuilding.
